Welcome to the REVLIMID REMS® program


Important information about REVLIMID and the REVLIMID Risk Evaluation
and Mitigation Strategy (REMS) program

  • REVLIMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with REVLIMID provided adequate precautions are taken to avoid pregnancy

  • To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called "REVLIMID REMS®"

  • Only prescribers and pharmacies certified by the REVLIMID REMS® program can prescribe and dispense REVLIMID to patients who are enrolled and meet all the conditions of the REVLIMID REMS® program

The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:

  1. To prevent the risk of embryo-fetal exposure to REVLIMID

  2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: